Cargando…

Proteomic analysis to define predictors of treatment response to adalimumab or methotrexate in rheumatoid arthritis patients

Seropositivity for anti-citrullinated peptide antibodies (ACPA) in patients with rheumatoid arthritis (RA), a chronic autoimmune arthritis, is associated with worse long-term disease outcomes. ACPA is ubiquitously tested in RA patients, but other autoantibodies exist (in both citrullinated and non-c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ling, Stephanie F., Nair, Nisha, Verstappen, Suzanne M. M., Barton, Anne, Zucht, Hans-Dieter, Budde, Petra, Schulz-Knappe, Peter, Plant, Darren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253356/ https://www.ncbi.nlm.nih.gov/pubmed/31819160 http://dx.doi.org/10.1038/s41397-019-0139-4

Ejemplares similares

Profiling of Gene Expression Biomarkers as a Classifier of Methotrexate Nonresponse in Patients With Rheumatoid Arthritis
por: Plant, Darren, et al.
Publicado: (2019)

Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis
por: Nair, Nisha, et al.
Publicado: (2020)

Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics
por: Maciejewski, Mateusz, et al.
Publicado: (2021)

Pre-defined gene co-expression modules in rheumatoid arthritis transition towards molecular health following anti-TNF therapy
por: Sutcliffe, Megan, et al.
Publicado: (2022)

Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis
por: Hum, Ryan M, et al.
Publicado: (2022)

Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab
por: Burmester, Gerd R, et al.
Publicado: (2017)

Changes in the illness perceptions of patients with rheumatoid arthritis over the first year of methotrexate therapy
por: Gwinnutt, James M, et al.
Publicado: (2020)

Sequential high-content profiling of the IgG-autoantibody repertoire reveals novel antigens in rheumatoid arthritis
por: Vordenbäumen, Stefan, et al.
Publicado: (2016)

Profiling of IgG antibodies targeting unmodified and corresponding citrullinated autoantigens in a multicenter national cohort of early arthritis in Germany
por: Vordenbäumen, Stefan, et al.
Publicado: (2020)

Predictors of presenteeism, absenteeism and job loss in patients commencing methotrexate or biologic therapy for rheumatoid arthritis
por: Gwinnutt, James M, et al.
Publicado: (2020)

Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial
por: Strand, Vibeke, et al.
Publicado: (2019)

Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis
por: Keystone, Edward C, et al.
Publicado: (2018)

Do people with rheumatoid arthritis maintain their physical activity level at treatment onset over the first year of methotrexate therapy?
por: Gwinnutt, James M, et al.
Publicado: (2021)

Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate
por: Humphreys, Jenny H, et al.
Publicado: (2017)

Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone
por: Keystone, Edward C, et al.
Publicado: (2017)

Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?
por: Chen, Hsin-Hua, et al.
Publicado: (2016)

Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate
por: Smolen, Josef S, et al.
Publicado: (2018)

Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels
por: Jani, Meghna, et al.
Publicado: (2016)

Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes
por: Hope, Holly F, et al.
Publicado: (2016)

Changes in Ultrasonographic Vascularity Upon Initiation of Adalimumab Combination Therapy in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
por: Kaeley, Gurjit S., et al.
Publicado: (2016)

Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial
por: Taylor, Peter C., et al.
Publicado: (2019)

Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate
por: Tkacz, Joseph, et al.
Publicado: (2020)

The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis
por: Incerti, Devin, et al.
Publicado: (2020)

Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study
por: Tanaka, Yoshiya, et al.
Publicado: (2016)

Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis
por: Kavanaugh, Arthur, et al.
Publicado: (2018)

Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
por: Gissel, C., et al.
Publicado: (2016)

Long-term treatment of rheumatoid arthritis with adalimumab
por: Murdaca, Giuseppe, et al.
Publicado: (2013)

Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study
por: Sherbini, Ahmad A, et al.
Publicado: (2022)

Nano Methotrexate versus Methotrexate in Targeting Rheumatoid Arthritis
por: Salem, Heba F., et al.
Publicado: (2022)

Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment
por: OIiver, James, et al.
Publicado: (2021)

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
por: Combe, Bernard, et al.
Publicado: (2021)

Correction to: Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment
por: Oliver, James, et al.
Publicado: (2021)

Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS)
por: Sergeant, Jamie C., et al.
Publicado: (2018)

Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis
por: Plant, Darren, et al.
Publicado: (2016)

Comprehensive exploratory autoantibody profiling in patients with early rheumatoid arthritis treated with methotrexate or tocilizumab
por: Teitsma, Xavier M., et al.
Publicado: (2020)

Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score
por: Gilani, Syed SA, et al.
Publicado: (2020)

Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis
por: Capsoni, Franco, et al.
Publicado: (2005)

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
por: Zhao, Sizheng, et al.
Publicado: (2018)

Sweet’s Syndrome in a Patient With Seropositive Rheumatoid Arthritis After Starting Adalimumab: Is Sweet’s Syndrome Related to Rheumatoid Arthritis or Is It the Paradoxical Effect of Adalimumab?
por: Paul, Prodip, et al.
Publicado: (2021)

Methotrexate alone and methotrexate combined with etanercept in treatment of rheumatoid arthritis
por: Rexhepi, Sylejman, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_tnopnktbifdnd239bj5qool290